Journal of Biological Chemistry · 2003 · 46 citations · 21 references
Life SciencesCell BiologyMolecular BiologyMolecular Cell BiologyMolecular OncologyTumor ProgressionCell Cycle BiochemistryCell Cycle TransitionsCell-cycle RegulationCyclin-dependent KinasesMitotic EntryProtein Kinase CascadesCyclin D FamilyCyclin-dependent Kinase ActivationCyclin-dependent Kinase PhosphorylationCyclin-dependent Kinase RegulationCyclinsP16ink4a RegulationPhosphorylation MotifsProtein Phosphorylation In Cell Cycle Regulation
Progression through the eukaryotic cell cycle is driven by the activity of cyclin-dependent kinases. The cyclin D-dependent kinase Cdk4 promotes progression through the G1 phase of the cell cycle and is deregulated in many human tumors. The tumor suppressor protein p16INK4A (p16) forms a complex with Cdk4 and inhibits kinase activity. Here we report that p16 is phosphorylated, and the phosphorylated form of p16 is preferentially associated with Cdk4 in normal human fibroblasts. We mapped phosphorylation sites on exogenously overexpressed p16 to serines 7, 8, 140, and 152 and found that endogenous p16 associated with Cdk4 is phosphorylated at serine 152. All mapped phosphorylation sites lie outside of the conserved kinase-binding domain of p16 but in regions of the protein affected by mutations in familial and sporadic cancer. Our results suggest a novel regulation of p16 activity. Progression through the eukaryotic cell cycle is driven by the activity of cyclin-dependent kinases. The cyclin D-dependent kinase Cdk4 promotes progression through the G1 phase of the cell cycle and is deregulated in many human tumors. The tumor suppressor protein p16INK4A (p16) forms a complex with Cdk4 and inhibits kinase activity. Here we report that p16 is phosphorylated, and the phosphorylated form of p16 is preferentially associated with Cdk4 in normal human fibroblasts. We mapped phosphorylation sites on exogenously overexpressed p16 to serines 7, 8, 140, and 152 and found that endogenous p16 associated with Cdk4 is phosphorylated at serine 152. All mapped phosphorylation sites lie outside of the conserved kinase-binding domain of p16 but in regions of the protein affected by mutations in familial and sporadic cancer. Our results suggest a novel regulation of p16 activity. cyclin-dependent kinase p16INK4A p21CIP1 p27KIP1 immunoprecipitate Dulbecco's modified Eagle's medium fetal bovine serum 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid high pressure liquid chromatography Progression through the cell cycle is driven by the activity of cyclin-dependent kinases (Cdks)1 (1Morgan D.O. Annu. Rev. Cell Dev. Biol. 1997; 13: 261-291Crossref PubMed Scopus (1815) Google Scholar). An active Cdk holoenzyme consists of a catalytic kinase subunit associated with a regulatory cyclin partner (1Morgan D.O. Annu. Rev. Cell Dev. Biol. 1997; 13: 261-291Crossref PubMed Scopus (1815) Google Scholar). Cdk4 promotes progression through the G1 phase of the cell cycle in response to extracellular growth signals (2Matsushime H. Ewen M.E. Strom D.K. Kato J.Y. Hanks S.K. Roussel M.F. Sherr C.J. Cell. 1992; 71: 323-334Abstract Full Text PDF PubMed Scopus (783) Google Scholar). The D-type cyclins promote Cdk4 activity; however, cellular cyclin D and Cdk4 associate only in response to additional growth factor-dependent signaling events (3Sherr C.J. Roberts J.M. Genes Dev. 1999; 13: 1501-1512Crossref PubMed Scopus (5178) Google Scholar, 4LaBaer J. Garrett M.D. Stevenson L.F. Slingerland J.M. Sandhu C. Chou H.S. Fattaey A. Harlow E. Genes Dev. 1997; 11: 847-862Crossref PubMed Scopus (1229) Google Scholar). Such events include the recruitment of assembly proteins such as p21CIP1 (p21) and p27KIP1(p27) to the Cdk4 complex (3Sherr C.J. Roberts J.M. Genes Dev. 1999; 13: 1501-1512Crossref PubMed Scopus (5178) Google Scholar, 4LaBaer J. Garrett M.D. Stevenson L.F. Slingerland J.M. Sandhu C. Chou H.S. Fattaey A. Harlow E. Genes Dev. 1997; 11: 847-862Crossref PubMed Scopus (1229) Google Scholar). Thus, the formation of an active cyclin D·Cdk4 complex is a highly regulated event (3Sherr C.J. Roberts J.M. Genes Dev. 1999; 13: 1501-1512Crossref PubMed Scopus (5178) Google Scholar). p16 is a specific inhibitor of the D-type Cdks (5Serrano M. Hannon G.J. Beach D. Nature. 1993; 366: 704-707Crossref PubMed Scopus (3403) Google Scholar). p16 association with Cdk4 results in dissociation of the D-cyclin and other assembly factors such that an inactive p16·Cdk4 complex contains no other proteins (6Parry D. Mahony D. Wills K. Lees E. Mol. Cell. Biol. 1999; 19: 1775-1783Crossref PubMed Scopus (157) Google Scholar). In contrast to the assembly of an active Cdk4 complex, current models presume that the assembly of an inactive p16·Cdk4 complex is regulated only by the abundance of the two proteins (3Sherr C.J. Roberts J.M. Genes Dev. 1999; 13: 1501-1512Crossref PubMed Scopus (5178) Google Scholar). Post-translational regulation of either p16 or a p16·Cdk4 complex has not been described. Furthermore, past studies have determined that p16 is not phosphorylated (7Thullberg M. Bartkova J. Khan S. Hansen K. Ronnstrand L. Lukas J. Strauss M. Bartek J. FEBS Lett. 2000; 470: 161-166Crossref PubMed Scopus (68) Google Scholar). Here we report that p16 is phosphorylated and map the phosphorylation sites to regions of the protein outside of the kinase-binding domain. We show that phosphorylation site mutants of p16 associate with Cdk4 as wild type p16 but that the phosphorylated form of p16 is selectively associated with Cdk4 in normal human fibroblasts. Our results suggest novel post-translational regulation of p16 activity. WI-38 and U2OS cells were obtained from the American Type Culture Collection and maintained in DMEM + 10% fetal bovine serum (FBS, Invitrogen). WI-38 cells were used at passage 3–5. U2OS cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. Wild type p16 and all Cdk4 plasmids have been described elsewhere (8Koh J. Enders G.H. Dynlacht B.D. Harlow E. Nature. 1995; 375: 506-510Crossref PubMed Scopus (524) Google Scholar). p16 phosphorylation site mutants were constructed using the QuikChange kit (Stratagene). For 35S labeling, cells were washed twice in phosphate-buffered saline and incubated for 20 min in methionine/cysteine-free DMEM (Invitrogen) supplemented with 10% dialyzed FBS (Hyclone). The medium was aspirated, and fresh medium was added containing 0.2mCi/ml Easy Tag Express protein labeling mix (PerkinElmer Life Sciences). The cells were labeled for 3 h before lysis and immunoprecipitation. For [32P]orthophosphate labeling, cells were washed twice in phosphate-free DMEM and incubated for 30 min in phosphate-free DMEM supplemented with 10% dialyzed FBS. The medium was aspirated and replaced with medium containing 1mCi/ml [32P]orthophosphate (PerkinElmer Life Sciences). The cells were incubated for 4 h prior to lysis and immunoprecipitation. Cells were lysed in ELB (50 mm HEPES, pH 7.0, 0.1% Nonidet P-40, 250 mm NaCl, 5 mm EDTA, 20 mm sodium fluoride, 2 mm sodium orthovanadate, and 1 mmdithiothreitol containing one complete miniprotease inhibitor tablet/10 ml (Roche Molecular Biochemicals)). The cells were incubated for 10 min on ice and clarified by centrifugation at 20,000 × gfor 10 min. The supernatant was transferred to a clean tube and immunoprecipitated with the indicated antibody: p16 (JC-4; Ref. 9Dai C.Y. Furth E.E. Mick R. Koh J. Takayama T. Niitsu Y. Enders G.H. Gastroenterology. 2000; 119: 929-942Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar), Cdk4 (Santa Cruz Biotechnology H-22), Myc tag (9E10 clone, laboratory stock), or a combination of normal mouse serum and rabbit serum (Jackson Immunoresearch Laboratories, Inc.). Antibody complexes were captured with protein G-Sepharose (AmershamBiosciences). All immunoprecipitations were washed three times in ELB prior to further manipulation. For phosphatase treatment of the Cdk4 immunoprecipitate (IP) (Fig. 1 A), the Cdk4 IP was washed twice in supplied phosphatase buffer prior to incubation with λ-phosphatase (New England Biolabs) for 30 min at 30 °C. For blots, IPs were separated by SDS-PAGE and transferred to Immobilon P (Millipore). The membranes were probed as directed using a combination of JC-2 and JC-8 to detect p16 (9Dai C.Y. Furth E.E. Mick R. Koh J. Takayama T. Niitsu Y. Enders G.H. Gastroenterology. 2000; 119: 929-942Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar). Cdk4 was detected with Santa Cruz Biotechnology H-22. IPs were washed twice in water to remove salts. Bound proteins were eluted by vortexing gently for 20 min in 2-D buffer (160 μl total volume, 2-D buffer contained 7 m urea, 2 m thiourea, 8 mm dithiothreitol, 4% Chaps, and 0.2% Biolytes, pH 5–8 (Bio-Rad)). 125 μl of the reaction mixture was loaded onto a pH 5–8 2-D strip (Bio-Rad) and focused according to the manufacturer's instructions. Following focusing, the strip was reduced, alkylated, and subjected to SDS-PAGE as instructed. Proteins from the resulting gel were transferred to Immobilon-P, and the labeled proteins were detected by autoradiography. Identity of the proteins was confirmed by blotting. The remaining volume of sample in 2-D buffer was separated by one-dimensional SDS-PAGE. Phosphoamino acid analysis was performed as recommended on a Hunter Thin Layer Chromatography peptide mapping system (C.B.S. Scientific). Separation in the first dimension was performed at pH 1.9 and in the second at pH 3.5 (10Boyle W.J. van der Geer P. Hunter T. Methods Enzymol. 1991; 201: 110-149Crossref PubMed Scopus (1276) Google Scholar). Separation of phosphorylated peptides by HPLC was performed as described previously (10Boyle W.J. van der Geer P. Hunter T. Methods Enzymol. 1991; 201: 110-149Crossref PubMed Scopus (1276) Google Scholar). Briefly, phosphorylated p16 was immunoprecipitated and separated by SDS-PAGE. Labeled p16 was excised from the gel and digested with sequencing grade trypsin (Promega). The resulting tryptic peptides were separated by HPLC over a Sephasil Peptide C8 column (AmershamBiosciences). For HPLC, buffer A was 0.065% trifluoroacetic acid, and buffer B was 50% acetonitrile, 0.057% trifluoroacetic acid. A gradient of 0–70% buffer B was run over 30 column volumes followed by elution with 100% buffer B for 5 column volumes (column volume was 1.65 ml). Scintillation counting of the resulting fractions was performed with a Wallac 1409 DSA liquid scintillation counter (PerkinElmer Life Sciences). Normal human fibroblasts (WI-38 cells) were labeled with35S-protein labeling mix, and either p16 or Cdk4 was immunoprecipitated. A single protein of approximate molecular mass 16 kDa was present in each IP but not in control reactions (Fig. 1 A, top). The identity of this protein was confirmed as p16 by Western blot (Fig.1 B). When separated by isoelectric focusing, two major populations of p16 were present in these cells. Of the two populations, a single species was associated with Cdk4 (Fig. 1 A, compare IP : p16 to IP : cdk4). Upon alignment, the species appeared to be the more acidic form of p16. To test whether the form of p16 associated with Cdk4 was phosphorylated, the Cdk4 IP was treated with λ-phosphatase for 30 min prior to separation. Treatment with phosphatase caused the appearance of a second, less acidic form of p16. These results suggested that a phosphorylated form of p16 is associated with Cdk4 in WI-38 cells. To confirm phosphorylation of p16, WI-38 cells were labeled with [32P]orthophosphate. p16 recovered from these lysates had incorporated 32P (Fig. 1 B, lower panel), demonstrating that p16 is a phosphoprotein. Moreover, p16 recovered in the Cdk4 IP was greatly enriched for phospho-p16. This was not due to increased recovery of p16 since the abundance of p16 in the Cdk4 IP was lower by Western blot. The reason for incomplete recovery of p16 in the p16 IP is unclear, but it is possible that phosphorylation results in decreased availability of the epitope (11Scott P.H. Brunn G.J. Kohn A.D. Roth R.A. Lawrence Jr., J.C. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 7772-7777Crossref PubMed Scopus (414) Google Scholar). Together with the isoelectric focusing results from Fig. 1 A, these data demonstrate that a phosphorylated form of p16 is preferentially associated with Cdk4 in cultured normal human fibroblasts. p16 is expressed at low levels in early passage WI-38 cells. We thus mapped phosphorylation sites on exogenous p16 to obtain sufficient protein for analysis. Myc-tagged p16 was overexpressed in p16-null U2OS cells, a human osteosarcoma cell line. The cells were labeled with [32P]orthophosphate, and exogenous p16 was isolated via the Myc tag. We found that exogenous p16 was exclusively serine-phosphorylated (Fig.2 A) just like endogenous p16 (data not shown). The labeled protein was digested with trypsin following separation by SDS-PAGE. The peptide digests were then separated by HPLC. An acetonitrile gradient was used to elute proteins from a C8 column so that larger, more hydrophobic peptides tend to elute later in the run. Scintillation counting of each fraction following the separation demonstrated the presence of three distinct phosphopeptides (Fig. 2 B, top panel). Fractions containing each labeled peptide were pooled, concentrated, and subjected to Edman degradation. Scintillation counting of the amino acid released following each round of degradation allowed identification of the phosphorylation sites in overexpressed p16. Each of the three labeled peptides contained different phosphorylation sites. These sites were mapped as serines 7 and 8, serine 140, and serine 152 (for mapping details and data, see Supplemental Figs. 1 and 2). We believe that both serine 7 and serine 8 can be phosphorylated because mutating either residue to alanine did not completely abrogate phosphorylation of this peptide. However, a p16 mutant lacking the eight N-terminal amino acids did not yield a corresponding N-terminal phosphopeptide. Similarly mutation of serine 152 to alanine abolished the presence of the serine 152 peak. The peak corresponding to serine 140 maps to a partial digestion product. The appearance of this peak was variable, probably due to the efficiency of digestion. We believe the completely digested peptide containing phosphorylated serine 140 does not bind the column. However, serine 140 is the only amino acid in p16 that is capable of being phosphorylated and maps correctly to a potential tryptic peptide following Edman degradation. We then asked which of these sites were phosphorylated on endogenous p16. p16 isolated from 32P-labeled WI-38 cells was digested and assayed for phosphorylation as above. We detected a single reproducible peak following labeling and digestion of endogenous p16 with trypsin (Fig. 2 B, middle panel). This peak eluted in the fractions corresponding to phosphoserine 152 on exogenous p16 (Fig. 2 B, upper panel) and eluted very close to an artificially synthesized phosphopeptide similar to the observed tryptic peptide (not shown). This peak was also present, even enriched, in p16 isolated by co-immunoprecipitation with Cdk4. We cannot rule out serine 140 phosphorylation in these IPs since the site maps to a partial tryptic digestion product. Similarly we could not rule out that other residues are phosphorylated at low levels, below the detection limit in our assay due to the low signal. However, by two-dimensional gel electrophoresis, we detect only two major species of p16 in WI-38 cells. Of particular interest was the location of the phosphorylation sites in human p16 (Fig. 3 A). These sites lie outside of the conserved kinase-binding region of p16 (12Russo A.A. Tong L. Lee J.O. Jeffrey P.D. Pavletich N.P. Nature. 1998; 395: 237-243Crossref PubMed Scopus (422) Google Scholar). The four ankyrin repeats that form the core structural unit of p16 are highly conserved between species; however, the regions surrounding the mapped phosphorylation sites are not conserved. The lack of conservation would suggest either that p16 phosphorylation is not important or that human p16 has acquired characteristics not shared between species. The correlation between p16 phosphorylation and Cdk4 association suggests the latter. In fact, at least two reports suggest functional differences between mouse and human p16 (13Smogorzewska A. de Lange T. EMBO J. 2002; 21: 4338-4348Crossref PubMed Scopus (373) Google Scholar, 14Brookes S. Rowe J. Ruas M. Llanos S. Clark P.A. Lomax M. James M.C. Vatcheva R. Bates S. Vousden K.H. Parry D. Gruis N. Smit N. Bergman W. Peters G. EMBO J. 2002; 21: 2936-2945Crossref PubMed Scopus (188) Google Scholar). To determine whether the phosphorylation sites on p16 are required for Cdk4 association, we mutated each of the sites to alanine, treating the adjacent serines 7 and 8 as a single site (p16 S7A/S8A). We expressed these mutants in p16-null U2OS cells at varying levels and compared association with Cdk4 (Fig. 3 B). In the experiment shown, the cells were transiently transfected with plasmids expressing untagged p16 constructs driven by a retroviral long terminal repeat. In our experiments, these vectors yield lower expression than the more commonly used cytomegalovirus promoter (data not shown). To ensure transfection of equal cell numbers, the amount of total DNA was held at a constant 2 μg, consisting of increasing amounts of p16 DNA together with the appropriate amount of empty vector. Even when expressed at low levels, each p16 mutant was present in a Cdk4 IP at levels comparable to wild type p16. Moreover, a Myc-tagged p16 construct consisting of only amino acids 9–139 of the protein and lacking all phosphorylation sites still associates with Cdk4 and inhibits cell cycle progression, although the construct appears less stable than wild type p16 (data not shown). These results indicate that phosphorylation of p16 does not in increased association with Cdk4. We have that p16 is phosphorylated and that the phosphorylated form of p16 is preferentially associated with Cdk4 in normal human fibroblasts. We have mapped phosphorylation sites on exogenous p16 to regions outside of the kinase-binding of the least one of these serine is phosphorylated on endogenous p16 in WI-38 cells. We have further that p16 phosphorylated at this site is associated with Cdk4 in WI-38 cells. models could the association of phosphorylated p16 with Cdk4. The first is that phosphorylation of p16 promotes association with Cdk4. The that phosphorylation site mutants to associate with Cdk4 this but these results are from studies in an cell and the in normal human fibroblasts. of p16 mutants in normal fibroblasts are by the presence of wild type p16 and in of a The second is that phosphorylation of p16 is a of association with Cdk4. We are this and the does not the is the of p16 of p16 does not the abundance or the of endogenous Cdk4 (data not shown). is that phosphorylation of p16 results in of an inactive p16·Cdk4 p16 has three and A. Hannon G.J. 1998; Google Scholar). Each of these has for Cdk4 equal to that of p16 (6Parry D. Mahony D. Wills K. Lees E. Mol. Cell. Biol. 1999; 19: 1775-1783Crossref PubMed Scopus (157) Google Scholar, M. Bartkova J. Khan S. Hansen K. Ronnstrand L. Lukas J. Strauss M. Bartek J. FEBS Lett. 2000; 470: 161-166Crossref PubMed Scopus (68) Google however, and not associate with Cdk4 in cells in which is expressed (6Parry D. Mahony D. Wills K. Lees E. Mol. Cell. Biol. 1999; 19: 1775-1783Crossref PubMed Scopus (157) Google Scholar). Furthermore, it has been that forms complexes with Cdk4 only it has to the kinase prior to and that cannot complexes J. Genes Dev. 1997; 11: PubMed Scopus Google Scholar). A regulatory that or a complex could p16 appears to be the Cdk4 inhibitor in cells expressing and The phosphorylation sites mapped in human p16 are for which an J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). We believe that Cdk4 does not p16 because the mapped sites are Cdk4 levels of p16 phosphorylation high even in the presence of a form of and Cdk4 does not p16 in not shown). be of interest to the kinases for p16 phosphorylation and determine the these kinases in cell cycle The phosphorylation sites mapped in human p16 could events associated with of the p16 is the mutations in human and many of familial are associated with of this M. Peters G. 1998; PubMed Scopus Google Scholar). The of mutations abrogate the of p16 to associate with kinase and the region of an tumor M. Peters G. 1998; PubMed Scopus Google Scholar). Of however, are mutations that p16 and not the of p16 for Cdk4 M. Peters G. 1998; PubMed Scopus Google Scholar). The of these mutations the that at least one such is associated with familial M. Peters G. 1998; PubMed Scopus Google Scholar). This mutation is a of the region the eight amino acids of p16 the serines potential phosphorylation sites G.J. C.J. J.M. Mol. 1995; PubMed Scopus Google Scholar, M. R. Gruis N. E. S. Peters G. J. P. Mol. 1997; PubMed Scopus Google Scholar). of the eight amino acids has also been as a mutation R. J. K. J. 1998; PubMed Scopus Google Scholar, A. H. S. R. J. J. 1995; PubMed Scopus Google Scholar). The proteins by the mutant p16 like wild type p16 in previously described for M. Peters G. 1998; PubMed Scopus Google Scholar). data have been mutations at the of p16 M. Peters G. 1998; PubMed Scopus Google Scholar). mutation of p16 and results in an of the four amino acids for the amino acids M. Peters G. 1998; PubMed Scopus Google Scholar, C.J. P.A. M.D. Clark Jr., PubMed Scopus Google Scholar, L. A. D. Ewen M.E. 1995; Google Scholar). A mutation the p16 and the by amino acids M. 1997; Google Scholar). the proteins by these are not in Cdk4 association, it has been to these mutations would be associated with M. Peters G. 1998; PubMed Scopus Google Scholar). All of the mutations regions of p16 the mapped phosphorylation sites. the of p16 phosphorylation unclear, two a for p16 phosphorylation in protein phosphorylated p16 is selectively associated with Cdk4 in normal human fibroblasts. phosphorylated regions of the protein are found mutated in and these mutations not of the such p16 mutants in for suggests that novel be to differences for p16 phosphorylation site of the by which p16 phosphorylation be of interest in p16 Cdk4 activity and as a tumor We and of the and for to this with
21
New functional activities for the p21 family of CDK inhibitors.
Joshua LaBaer, Michelle D. Garrett, Lauren Stevenson et al. · Genes & Development · 1997 · 1.4K citations · Full text
Germline p16 mutations in familial melanoma
Christopher J. Hussussian, Jeffery P. Struewing, Alisa M. Goldstein et al. · Nature Genetics · 1994 · 1.3K citations
Life Sciences, Genetics, Oncology +14